Compare BLX & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLX | WVE |
|---|---|---|
| Founded | 1977 | 2012 |
| Country | Panama | Singapore |
| Employees | 372 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 1997 | 2015 |
| Metric | BLX | WVE |
|---|---|---|
| Price | $53.77 | $6.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $29.81 |
| AVG Volume (30 Days) | 119.3K | ★ 3.9M |
| Earning Date | 04-27-2026 | 04-28-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $18.36 | N/A |
| Revenue Next Year | $9.95 | $85.67 |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $38.41 | $5.02 |
| 52 Week High | $57.79 | $21.73 |
| Indicator | BLX | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 33.83 |
| Support Level | $52.31 | $5.02 |
| Resistance Level | $55.30 | $7.65 |
| Average True Range (ATR) | 1.34 | 0.37 |
| MACD | -0.25 | 0.06 |
| Stochastic Oscillator | 51.65 | 24.40 |
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.